2024-11-21T14:35:45-06:00 2023-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2023-01-01 911608978 ACCESS TO ADVANCED HEALTH INSTITUTE ACCE 2063810883 1616 EASTLAKE AVE E 400 SEATTLE WA 98102 JERRY KUO CFOO 2063810883 2024-11-21 1 0 MEGAN R RYAN P00737884 4254544919 2024-11-21 2023 2024-10-15 13:58:12Z INFECTIOUS DISEASE RESEARCH INSTITUTE JERRY KUO 1616 EASTLAKE AVE E 400 SEATTLE WA 98102 23393018 0 X WWW.AAHI.ORG X 1993 WA DEVELOP VACCINES, ADJUVANTS, DIAGNOSTICS & DRUGS TO PREVENT, DETECT & TREAT INFECTIOUS DISEASES OF GLOBAL IMPORTANCE. 7 5 89 6 31673 11291 33420108 11574469 17386494 10631521 61987 345516 317665 224869 51186254 22776375 0 0 0 0 9652019 11489626 0 0 0 11710438 12326239 21362457 23815865 29823797 -1039490 42840477 39831178 16927712 14794761 25912765 25036417 X AAHI IS A NONPROFIT BIOTECH RESEARCH INSTITUTE, BRINGING TOGETHER THE BEST EXPERTS, TECHNOLOGIES, AND PLATFORMS TO CREATE ACCESSIBLE, HIGH-QUALITY PRODUCTS AND SOLUTIONS FOR HARNESSING THE IMMUNE SYSTEM TO ALLEVIATE DISEASE. 0 0 5911795 3748408 FORMULATIONS - ADJUVANTS ARE POWERFUL IMMUNE-STIMULATING MOLECULES THAT INCREASE THE EFFICACY OF VACCINES AND ENHANCE THE IMMUNE SYSTEM'S ABILITY TO DESTROY TUMORS. AAHI HAS AMONG THE LARGEST PORTFOLIOS OF ADJUVANTS; IMPORTANTLY, AAHI SCIENTISTS FORMULATE THESE MOLECULES IN A WAY THAT MAKES THEM MINIMALLY TOXIC AND MAXIMALLY POTENT. IN PARTNERSHIP WITH VACCINE DEVELOPERS ACROSS THE WORLD, MANY AAHI ADJUVANT FORMULATIONS HAVE BEEN SAFELY ADMINISTERED TO THOUSANDS OF PEOPLE IN RIGOROUS CLINICAL TRIALS. AAHI'S ADJUVANT FORMULATIONS NOW ARE IN LEADING VACCINE CANDIDATES AGAINST HIV, TUBERCULOSIS, MALARIA, AND A MYRIAD OF OTHER INFECTIOUS DISEASES. 4692227 1613768 MANUFACTURING AND CLINICAL SUPPORT - AAHI'S IN-HOUSE MANUFACTURING CAPABILITIES SUPPORT RAPID SCALE-UP AND PRODUCTION OF VACCINES FOR USE IN PHASE 1 AND PHASE 2 CLINICAL TRIALS AND COMPLETE AAHIS'S UNIQUE VACCINE DISCOVERY-DEVELOPMENT PROCESS. AAHI'S RESEARCH SCIENTISTS AND FORMULATIONS/PROCESS DEVELOPMENT TEAMS WORK WITH AAHI'S MANUFACTURING EXPERTS TO DEVELOP MANUFACTURING PROCESSES TO PRODUCE VACCINE CANDIDATES UNDER CONTROLLED CONDITIONS SO THATTHEY ARE SUITABLE FOR USE IN HUMAN STUDIES. THIS ENABLES AAHI TO QUICKLY AND EFFICIENTLY MOVE A VACCINE FROM LATE-STAGE RESEARCH TO EARLY PHASE CLINICAL STUDIES. AAHI CONSULTS LATER STAGE CLINICAL STUDIES. AAHI'S MANUFACTURING SUITE FOLLOWS US FDA "GOOD MANUFACTURING PRACTICE" REGULATIONS AND IS AN INVALUABLE RESOURCE TO AAHI SCIENTISTS AND BIOTECHNOLOGY DEVELOPERS IN THE NON-PROFIT, ACADEMIC, AND FORPROFIT SECTORS. 3658916 5267829 RNA VACCINES - RNA VACCINES HAVE BEEN SHOWN TO BE CRITICAL TOOLS FOR COMBATTING PANDEMICS AND HAVE BEEN SAFELY ADMINISTERED TO BILLIONS OF PEOPLE ACROSS THE GLOBE. AAHI'S RNA VACCINE PLATFORM IS DISTINCT FROM EXISTING LICENSED RNA VACCINES IN THAT IT IS BASED ON A SELF-AMPLIFYING RNA TECHNOLOGY AND DELIVERED BY A FLEXIBLE NANOSTRUCTURED LIPID CARRIER. TOGETHER, THESE FEATURES MEAN THAT THE VACCINE COULD BE STOCKPILED FOR YEARS, DELIVERED AT ROOM TEMPERATURE, AND MORE RAPIDLY MANUFACTURED TO ADDRESS FUTURE PANDEMICS. AAHI SCIENTISTS ARE ADVANCING RNA VACCINES AGAINST COVID-19, INFLUENZA, YELLOW FEVER, ZIKA, CHIKUNGUNYA, AND HIV, AND ADAPTING THE PLATFORM TO BE DELIVERED BY NASAL SPRAY OR DIRECTLY ADMINISTERED INTO TUMORS. 363429 1516 PROCESS AND PRODUCT DEVELOPMENT - MODERN VACCINES ARE INCREASINGLY COMPLEX AND THEIR DESIGN NEEDS TO BE TAILORED TO SPECIFIC TARGET PRODUCT PROFILES TO ENSURE PRACTICAL ACCESSIBILITY. SUSTAINABLE SOURCING OF RAW MATERIALS, STREAMLINED MANUFACTURING METHODS, AND TEMPERATURE STABILITY ARE CRITICALLY IMPORTANT TO ENABLE VACCINES FOR GLOBAL HEALTH APPLICATIONS IN RESOURCE-LIMITED SETTINGS. ALTERNATIVE ROUTES OF ADMINISTRATION, SUCH AS INTRANASAL DELIVERY, NOT ONLY MAY BEST BE SUITED TO FIGHT RESPIRATORY PATHOGENS BUT ALSO HELP TO ADDRESS VACCINE HESITANCY AND TO INCREASE VACCINE UPTAKE. AAHI SCIENTISTS ARE WORLD-EXPERTS AT DEVELOPING PROCESSES AND METHODS TO ADVANCE NOVEL PRODUCTS THAT MEET THE NEEDS OF VACCINE DEVELOPERS BOTH WITHIN AAHI AND EXTERNALLY AMONG THE DOZENS OF ACADEMIC, NON-PROFIT, AND COMMERCIAL PARTNERS. 363429 1516 14626367 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 1 29 0 89 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 7 5 1 0 0 0 0 0 0 1 1 0 0 0 1 1 0 1 1 1 1 0 X SUZAN SNODGRASS 2068586025 1616 EASTLAKE AVE E SUITE 400 SEATTLE WA 98102 COREY CASPER CEO, PRESIDENT 40.00 X X 542213 0 41463 PATRICK SOON-SHIONG BOARD CHAIR 0.50 X X 0 0 0 DAVID KERR BOARD MEMBER 0.50 X 0 0 0 EDWARD MOCARSKI BOARD MEMBER 0.50 X 0 0 0 EDWARD HSU BOARD MEMBER 0.50 X 0 0 0 GLENDA GRAY BOARD MEMBER 0.50 X 0 0 0 RAOUL CONCEPCION BOARD MEMBER 0.50 X 0 0 0 CANDICE DECAIRE CHIEF STRATEGY OFFICER, SECRETARY 40.00 X 348290 0 40791 JERRY KUO CFOO, V.P. & TREASURER 40.00 X 344534 0 55747 ANNA MARIE BECKMANN EVP, PRODUCT DEVELOPMENT 40.00 X 280027 0 42086 CHRISTOPHER FOX SENIOR VP OF FORMULATIONS 32.00 X 236068 0 55214 LINDA HAWKINS SENIOR DIR. QUALITY ASSURANCE 40.00 X 228348 0 40634 ROBRICK SMITH DIRECTOR, INFORMATION TECHNOLOGY 40.00 X 192601 0 46265 SUZAN SNODGRASS DIRECTOR, FINANCE 40.00 X 184714 0 33380 ANDREW JOHNSON ASSOCIATE DIRECTOR, PROGRAM MGMT 40.00 X 176746 0 23630 DARREN KLEMKOW DIR. FACILITIES & PROCUREMENT 40.00 X 167930 0 22557 EMILY VOIGT DIR. RNA PROGRAM 40.00 X 166818 0 42091 LISA MCNEILL DIR. MANUFACTURING 36.00 X 162652 0 33698 LISA BOUCHARD DIR. QUALITY CONTROL 40.00 X 156372 0 31035 JEFFREY GUDERIAN DIR. LABORATORY MANAGEMENT 40.00 X 154096 0 31704 ZACHARY SAGAWA DIR. CLINICAL RESEARCH & REG. AFFAIRS 40.00 X 153333 0 35414 DAMON PANG SENIOR CORPORATE COUNSEL 40.00 X 133466 0 34084 CRISTINA GOMAN CLINICAL TRIAL MANAGER 40.00 X 129357 0 9837 ROBERT KINSEY SENIOR MANAGER, FORMULATIONS 40.00 X 126960 0 20533 AMY SEMENOV DIR. HUMAN RESOURCES 40.00 X 124625 0 36039 THERESA BRITSCHGI SENIOR PROJECT MANAGER 40.00 X 124110 0 20445 4133260 0 696647 30 0 1 0 NEWPORT IP LLC 1400 112TH AVE SE SUITE 100 BELLEVUE WA 98004 LEGAL 232526 REINHARD VEHRING 25 WILLOW STREET READING MA 01867 CONSULTING 220194 ASCENDANT STRATEGIC PARTNERS 3040 MANOR PLACE DRIVE ROSWELL GA 30075 CONSULTING 127798 CLARK NUBER 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 ACCOUNTING 124375 4 8899024 2675445 11574469 LICENSING 541700 6212068 6212068 SERVICES AND CONTRACTS 541700 4419453 4419453 10631521 329916 329916 833572 616643 216929 216929 31673 185256 15600 0 15600 15600 15600 REIMBURSEMENTS 900099 8057 8057 FX GAIN/LOSS 900099 -117 -117 7940 22776375 10631521 31673 538712 4070450 1953816 2116634 5577081 3742293 1834788 283803 191288 92515 808333 528791 279542 749959 448047 301912 639363 639363 115189 115189 2068840 1647953 420887 161409 59460 101949 489227 1433 487794 187284 187284 1940259 1596661 343598 57176 13984 43192 16187 5582 10605 1408580 538728 869852 170460 170460 LAB SUPPLIES 1692152 1692152 SUBCONTRACTS 1600601 1600601 BAD DEBT 489807 103694 386113 REPAIRS & MAINTENANCE 467143 464530 2613 822562 37354 785208 23815865 14626367 9189498 0 5799234 6910935 1116207 7634175 16839707 8000000 4108085 3252663 746871 554982 651552 649750 22369032 16487562 5622236 5881470 1090104 1025031 6866481 5922172 42840477 39831178 1566507 2740093 2788673 1311721 12572532 10742947 16927712 14794761 X 9076058 17036417 16836707 8000000 25912765 25036417 42840477 39831178 X -1039490 2849 160293 X X 0 0 1 0 X 11251999 3584439 6701932 33420108 11574469 66532947 11251999 3584439 6701932 33420108 11574469 66532947 25196598 41336349 13436 532 622450 833118 1131815 2601351 12382 15171 12291 39844 -13 193881 5587477 121629 7940 5910914 75085056 63048226 0.55050 0.56310 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2020 AMOUNT: $ 5,857. 2021 AMOUNT: $ 13,195. 2022 AMOUNT: $ 801. REIMBURSEMENTS - 2020 AMOUNT: $ 121,334. 2021 AMOUNT: $ 22,534. 2022 AMOUNT: $ 13,393. REFUNDS REIMBURSEMENTS - 2019 AMOUNT: $ -13. 2020 AMOUNT: $ 66,690. 2021 AMOUNT: $ 19,248. 2022 AMOUNT: $ 7,435. 2023 AMOUNT: $ 7,940. LITIGATION SETTLEMENT - 2021 AMOUNT: $ 5,532,500. 2022 AMOUNT: $ 100,000. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 11377971 8163249 3214722 10357077 8324313 2032764 633984 633984 5881470 RIGHT-OF-USE ASSET 5922172 5922172 OPERATING LEASE LIABILITY 10382947 SETTLEMENTS PAYABLE 360000 10742947 EAST ASIA AND THE PACIFIC 0 0 LEGAL N/A 24151 EUROPE (INCLUDING ICELAND AND GREENLAND) 0 0 PROGRAM SERVICE SUBCONTRACT, SUPPLIES, LEGAL 366024 MIDDLE EAST AND NORTH AFRICA 0 0 LEGAL N/A 17907 NORTH AMERICA 0 0 PROGRAM SERVICE SUBCONTRACT, LEGAL 196749 RUSSIA AND NEIGHBORING STATES 0 0 LEGAL N/A 2529 SOUTH AMERICA 0 0 LEGAL N/A 5467 SOUTH ASIA 0 0 LEGAL N/A 24410 SUB-SAHARAN AFRICA 0 0 LEGAL N/A 286 0 0 0 0 0 0 637523 0 637523 1 0 0 0 0 0 SCHEDULE F, PART IV, LINE 1: FORM 926 IS NOT REQUIRED TO BE FILED BECAUSE THE TRANSFER TO A FOREIGN CORPORATION DOES NOT MEET THE REPORTING REQUIREMENTS IN THE IRC SEC. 6038(A)(1)(A). X X X 0 0 0 0 0 0 0 1 0 COREY CASPER CEO, PRESIDENT 542213 0 0 0 0 0 11050 0 30413 0 583676 0 0 0 JERRY KUO CFOO, V.P. & TREASURER 342134 0 0 0 2400 0 19800 0 35947 0 400281 0 0 0 CANDICE DECAIRE CHIEF STRATEGY OFFICER, SECRETARY 347190 0 0 0 1100 0 19800 0 20991 0 389081 0 0 0 ANNA MARIE BECKMANN EVP, PRODUCT DEVELOPMENT 279761 0 266 0 0 0 16996 0 25090 0 322113 0 0 0 CHRISTOPHER FOX SENIOR VP OF FORMULATIONS 184772 0 51296 0 0 0 14875 0 40339 0 291282 0 0 0 LINDA HAWKINS SENIOR DIR. QUALITY ASSURANCE 228082 0 266 0 0 0 13981 0 26653 0 268982 0 0 0 ROBRICK SMITH DIRECTOR, INFORMATION TECHNOLOGY 192323 0 278 0 0 0 10113 0 36152 0 238866 0 0 0 SUZAN SNODGRASS DIRECTOR, FINANCE 184451 0 263 0 0 0 11424 0 21956 0 218094 0 0 0 EMILY VOIGT DIR. RNA PROGRAM 158530 0 8288 0 0 0 10753 0 31338 0 208909 0 0 0 ANDREW JOHNSON ASSOCIATE DIRECTOR, PROGRAM MGMT 176387 0 359 0 0 0 10780 0 12850 0 200376 0 0 0 LISA MCNEILL DIR. MANUFACTURING 162363 0 289 0 0 0 9942 0 23756 0 196350 0 0 0 DARREN KLEMKOW DIR. FACILITIES & PROCUREMENT 167643 0 287 0 0 0 10418 0 12139 0 190487 0 0 0 ZACHARY SAGAWA DIR. CLINICAL RESEARCH & REG. AFFAIR 153044 0 289 0 0 0 9219 0 26195 0 188747 0 0 0 LISA BOUCHARD DIR. QUALITY CONTROL 156083 0 289 0 0 0 9642 0 21393 0 187407 0 0 0 JEFFREY GUDERIAN DIR. LABORATORY MANAGEMENT 153793 0 303 0 0 0 6304 0 25400 0 185800 0 0 0 DAMON PANG SENIOR CORPORATE COUNSEL 133152 0 314 0 0 0 8627 0 25457 0 167550 0 0 0 AMY SEMENOV DIR. HUMAN RESOURCES 124315 0 310 0 0 0 7497 0 28542 0 160664 0 0 0 PART I, LINE 7 BONUS AMOUNTS FOR THE CEO ARE DETERMINED BY THE BOARD OF DIRECTORS. THE CEO DETERMINES THE BONUS AMOUNTS FOR ALL OTHER EXECUTIVE STAFF. IMMUNITY BIO BOARD MEMBER >35% OWNER OF THE ORGANIZATION 6574703 ANNUAL LICENSING AGREEMENT, CONTRACT SERVICES, PRODUCT & MATERIALS PROCEEDS 0 FORM 990, PART I, LINE 6: ACCESS TO ADVANCED HEALTH INSTITUTE HAD SIX VOLUNTEER BOARD MEMBERS IN 2023. FORM 990, PART VI, SECTION A, LINE 2 PATRICK SOON-SHIONG AND DAVID KERR HAVE A BUSINESS RELATIONSHIP. PATRICK SOON-SHIONG AND RAOUL CONCEPCION HAVE A BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B A DRAFT OF THE FORM 990 IS REVIEWED BY THE COO & CFO AND DIRECTOR OF FINANCE. IN ADDITION, THE CHAIR OF THE FINANCE AND AUDIT COMMITTEE WILL REVIEW PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD ESTABLISHED A COMPENSATION COMMITTEE AND A COMPENSATION POLICY. COMPENSATION FOR THE CEO AND OTHER EXECUTIVE TEAM MEMBERS IS REVIEWED AND SET BY THE BOARD AFTER REVIEWING KEY PERFORMANCE INDICATORS FOR THE ORGANIZATION. FORM 990, PART VI, SECTION C, LINE 19 REQUESTS FOR INFORMATION SUCH AS AUDITED FINANCIAL STATEMENTS AND GOVERNING DOCUMENTS ARE HANDLED THROUGH OUR FINANCE DEPARTMENT AND INFORMATION IS DISTRIBUTED AS REQUESTED UNLESS CONFIDENTIAL IN NATURE. REQUESTS FOR THE CONFLICT OF INTEREST POLICY ARE HANDLED THROUGH THE LEGAL DEPARTMENT. FORM 990, PART XI, LINE 9: PRESENT VALUE ADJUSTMENT OF PLEDGE RECEIVABLE 160,293. FORM 990, PART XII, LINE 3B: AT THE TIME OF FILING FOR THE DECEMBER 31, 2023 FORM 990, ACCESS TO ADVANCED HEALTH INSTITUTE WAS UNDERGOING THE REQUIRED 2023 PROGRAM-SPECIFIC AUDIT. TIGER DEVELOPMENT LLC 3800 N CENTRAL AVE 460 PHOENIX AZ 85010 PATENT HOLDING COMPANY AZ 0 941176 ACCESS TO ADVANCED HEALTH INSTITUTE